- Report
- May 2024
- 139 Pages
Global
From €6207EUR$6,499USD£5,190GBP
- Drug Pipelines
- August 2024
- 60 Pages
Global
From €1194EUR$1,250USD£998GBP
- Report
- June 2024
- 200 Pages
Global
From €7593EUR$7,950USD£6,349GBP
- Report
- May 2024
- 133 Pages
Global
From €6207EUR$6,499USD£5,190GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1910EUR$2,000USD£1,597GBP
- Report
- February 2024
- 130 Pages
Global
From €7593EUR$7,950USD£6,349GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- October 2023
- 74 Pages
Global
From €3500EUR$3,926USD£3,029GBP
Usher Syndrome Drug is a type of drug used to treat a rare genetic disorder that affects the eyes and ears. It is a form of Central Nervous System (CNS) drug, which is used to treat a variety of neurological conditions. Usher Syndrome is a genetic disorder that affects the development of the eyes and ears, leading to hearing and vision loss. It is the most common cause of combined deaf-blindness in the world.
Usher Syndrome Drug is used to treat the symptoms of the disorder, such as hearing loss, vision loss, balance problems, and difficulty with coordination. It is also used to slow the progression of the disorder and to improve the quality of life of those affected. Treatment options include medications, hearing aids, cochlear implants, and vision aids.
The Usher Syndrome Drug market is a small but growing market, with a few companies developing treatments for the disorder. These companies include Genzyme, a Sanofi company, which is developing a gene therapy for Usher Syndrome; Spark Therapeutics, which is developing a gene therapy for Usher Syndrome; and ProQR Therapeutics, which is developing a RNA-based therapy for Usher Syndrome. Other companies in the market include Audentes Therapeutics, which is developing a gene therapy for Usher Syndrome, and Otonomy, which is developing a drug for Usher Syndrome. Show Less Read more